ALLIANCE RECEIVES POSITIVE OPINION FOR DICLECTIN
Alliance Pharma announces that the MHRA and the CHM have advised that the Marketing Authorisation Application for Diclectin® is now considered approvable
Read moreALEXION TO ACQUIRE WILSON THERAPEUTICS
Wilson Therapeutics AB announces public offer from Alexion Pharmaceuticals
Read moreMVM LEADS $28m FINANCING IN VERTOS MEDICAL, INC.
Vertos Medical, Inc. is a high growth leader in the minimally invasive treatment of lumbar spinal stenosis
Read moreMVM LEADS $33m SERIES C IN VITAL CONNECT, INC
Vital Connect, Inc. is a leader in medical-grade wearable biosensor systems
Read moreCLINICAL STUDY SUPPORTS CHEETAH'S TECHNOLOGY
A clinical study by the University of Kansas Health System reported strong clinical and health economic value for Cheetah Medical technology in sepsis.
Read moreMVM CLOSES MVM IV
MVM Partners LLP has announced the closing of a $233 million healthcare fund, MVM IV. The fund is MVM’s fourth and largest raised to date
Read moreMVM INVESTS €15.2 MILLION IN VALNEVA SE
Valneva is a commercial stage vaccine company with products to prevent Japanese encephalitis and cholera
Read moreMVM LEADS $10.5M FINANCING IN PROVIDENCE MEDICAL
Providence Medical Technology, Inc., a fast growth innovator in tissue-sparing, cervical-fusion technology, has announced the closing of $10.5 million in new equity financing
Read more
MVM Overview
- • An investor in high growth healthcare companies since 1997
- • More than $700 million under management across several funds
- • Investment teams in Boston and London provide global perspective and coverage
- • Partners of MVM have more than 110 years of healthcare investment experience
Recent News
Alliance Pharma receives positive opinion for Diclectin
Alliance Pharma plc (AIM: APH), the specialty pharmaceutical company, announces that, following discussions with the Medicines and Healthcare products Regulatory Agency and the Commission on Human Medicines, the Marketing Authorisation Application for Diclectin® is now considered approvable.
Wilson Therapeutics AB announces public offer from Alexion Pharmaceuticals
Alexion Pharmaceuticals, Inc., has today, through Alexion Pharma Nordics Holding AB, announced a public cash offer to Wilson Therapeutics’ shareholders for a consideration of SEK 232 per Wilson Therapeutics share in cash (the “Offer”), which corresponds to a total offer value of approximately SEK 6,564 million, based on 28,292,272 shares outstanding.